



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

VB

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/096,749 06/12/98 KOIDE

S 109.034US1

021186 HM22/0509
SCHWEGMAN LUNDBERG WOESSNER & KLUTH
P O BOX 2938
MINNEAPOLIS MN 55402

EXAMINER

HARRIS,A

ART UNIT	PAPER NUMBER
----------	--------------

1642

9

DATE MAILED:

05/09/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No.
09/096,749

Applicant(s)

Kolde

Examiner

Alana M. Harris, Ph. D.

Group Art Unit

1642



Responsive to communication(s) filed on _____

This action is FINAL.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle* 1035 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 0 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claim

Claim(s) 1-39 _____ is/are pending in the application

Of the above, claim(s) _____ is/are withdrawn from consideration

Claim(s) _____ is/are allowed.

Claim(s) _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claims 1-39 _____ are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1642

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-6, drawn to a fibronectin type III (Fn3) polypeptide monobody, classified in class 530, subclass 387.1.
 - II. Claims 7-10 and 14, drawn to an isolated nucleic acid molecule, classified in class 536, subclass 23.1.
 - III. Claim 11, drawn to a method of preparing a Fn3 polypeptide monobody comprising cleaving DNA, classified in class 435, subclass 68.1.
 - IV. Claim 12, drawn to a method of preparing a Fn3 polypeptide monobody comprising PCR, classified in class 435, subclass 91.2.
 - V. Claim 13, drawn to a method of preparing a Fn3 polypeptide monobody comprising site-directed mutagenesis, classified in class 435, subclass 69.1.
 - VI. Claims 15-29, 36 and 37, drawn to a variegated nucleic acid library, classified in class 536, subclass 23.5.
 - VII. Claim 30, drawn to a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP), classified in class 435, subclass 7.1.
 - VIII. Claim 31, drawn to a method of preparing a variegated nucleic acid library comprising contacting the polypeptide with a SBP, classified in class 435, subclass 69.1.

Art Unit: 1642

IX. Claim 32, drawn to a method of identifying the amino acid sequence of a polypeptide molecule comprising contacting the peptide display library with a transition state analog compound (TSAC), classified in class 435, subclass 7.1.

X. Claim 33, drawn to a method of preparing a variegated nucleic acid library comprising contacting the polypeptide with TSAC, classified in class 435, subclass 69.1.

XI. Claims 34, 35, 38 and 39 drawn to an isolated polypeptide, classified in class 530, subclass 350.

2. The inventions are distinct, each from the other because of the following reasons:

Groups I, II, VI and XI are structurally and functionally different products which are made by different methods and have different uses. The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

The methods of Groups III-V and VII-X differ in the method objectives, method steps and parameters and in the reagents used.

Inventions of Group II and Groups`III-V are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that

Art Unit: 1642

product (M.E.P.. § 806.05(h)). In the instant case the isolated nucleic acid molecule of Group II can be used in any one of method groups III-V.

Inventions of Groups XI and Groups VII-X are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.E.P.. § 806.05(h)). In the instant case the isolated polypeptides of Group XI can be used in any one method groups VII-X.

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Attempts to reach Ann S. Viksnins by telephone on April 25, 2000 to request an oral election to the above restriction requirement were unsuccessful.

Art Unit: 1642

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, whose telephone number is (703) 306-5880.



NANCY A. JOHNSON, PH.D
PRIMARY EXAMINER